Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set

Abstract

The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method. The invention also encompasses a therapeutic causing contraction of nasal mucosal tissue containing ethanol as the active ingredient preferably together with a steroid and / or an antihistaminic agent; a method of treating diseases with mucosal inflammation using the above therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method.

Description

INCORPORATION BY REFERENCE[0001]This application is a continuation-in-part application of international patent application Serial No. PCT / JP2003 / 012329 filed Sep. 26, 2003, which claims benefit of Japanese patent application Serial No. JP 2002-281321 filed Sep. 26, 2002.[0002]The foregoing applications, and all documents cited therein or during their prosecution (“appln cited documents”) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.FIELD OF THE INVENTION[0003]The present invention relates to a therapeutic causing contraction of mucosal tissu...

AI Technical Summary

Benefits of technology

[0029]The object of the present invention is to provide a therapeutic causing contraction of mucosal tissues whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of mucosal tissues, and an injector and a therapeutic set usable in the treatment method.

[0030]First, the present invention provides a therapeutic causing contraction of nasal mucosal tissues whereby various diseases relating to nasal mucosal tissues can be easily, safely and treated with minimal invasiveness, as well as a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of nasal mucosal tissues. Second, the present invention provides a therapeutic causing contraction of oral pharyngeal mucosal tissues whereby various diseases relating to oral pharyngeal mucosal tissues can be easily, safely and treated with minimal invasiveness, as well as a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of oral pharyngeal mucosal tissues. Third, the present invention provides an injector capable of successively injecting a therapeutic easily, safely and accurately and a therapeutic set equipped with the injector.

[0037]The present invention makes it possible to provide a therapeutic causing contraction of mucosal tissues whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of mucosal tissues, and an injector and a therapeutic set usable in the treatment method.

Problems solved by technology

Conventionally, oral medicines such as an anti-allergy agent, an antihistaminic agent and a steroid preparation have been administered in one kind of treatment of nasal diseases such as hypertrophic rhinitis, vasomotor rhinitis, allergic rhinitis and nasal polyp, but a majority of these oral medicines have a transient symptomatic effect, and the symptoms occur easily repeatedly, and successive use of the oral medicine for a long time is often regarded as difficult.

Further, occurrence of various side effects, for example drowsiness, dry mouth and disturbance in the liver, stomach and intestines is known.

However, the nasal mucosa resection, laser ablation and cryosurgery cause open and significant invasion in the mucosal surface and need a considerable time for recovery of the nasal mucosa once treated.

That is, these methods are based on open ablation in the mucosal surface, and thus mucosal erosion and scab formation are caused due to the damage to the mucosal surface for a long time after the operation, so that rhinitis is adversely worsened for a long time, to give physical and mental pains and unpleasant feeling to the patient.

Further, the therapeutic effect does often not reach the mucosa in a deep position where nerve fibers are actually present, and it is rare for all nasal conditions such as mucus and sneezes to be simultaneously and rapidly relieved.

However, the high-frequency tissue reducing method has the problem that the cost of introducing the system and the running cost are very high.

Moreover, it is actually confirmed that the surface of mucosa may be damaged for a long time after the treatment.

However, the idea of mucosal contraction by protein coagulation caused by injecting the alcohol directly to the submucosa has not been proposed.

This is possibly due to mucosal brittleness and the damage to tissue cells caused by ethanol.

That is, the killing power of ethanol which has been clinically used as a nerve blocking agent or a tumor-destroying agent, is so violent that upon direct injection of thin mucosal tissues, the problem of various complications may be caused, and thus attention has not been paid to the applicability of ethanol.

Images